Trends in Gastroparesis Management
- 10 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 57 (8) , 789-797
Abstract
Background: There is little consensus on the medical management of gastroparesis, a disorder characterized by delayed gastric emptying with symptoms of early satiety, nausea, vomiting, and upper abdominal pain. Goals: We utilized population-level data to: (1) describe the prevalence of different pharmacological and nonpharmacological therapies in patients with gastroparesis; and (2) trend the prevalence of these therapies from 2010 to 2020. Study: More than 59 million unique medical records across 26 US-based major health care systems were surveyed using the Explorys platform to identify a cohort of adults with gastroparesis who completed both a gastric emptying study and upper endoscopy or upper gastrointestinal tract imaging. Prevalence of antiemetic, prokinetic, neuromodulator prescriptions, and surgical therapies for gastroparesis were searched within this cohort and trended annually from 2010 to 2020. Results: Antiemetics (72% of patients), prokinetics (47%), and neuromodulators (75% of patients, 44% of patients without a concomitant psychiatric or diabetic peripheral neuropathy diagnosis) were all commonly used in the treatment of patients with gastroparesis. From 2010 to 2020, there was an increase in the prevalence of antiemetic and neuromodulator prescriptions (36.4% to 57.6%, PPP=0.52). Procedural and surgical treatments were used in 5% of gastroparesis patients. Conclusions: Treatments for gastroparesis have changed over the last decade: antiemetic and neuromodulator use has increased whereas prokinetic use has remained constant. This practice pattern may reflect the growing number and availability of antiemetics and neuromodulators and the small number and known side effects of prokinetics.Keywords
This publication has 21 references indexed in Scilit:
- Rome IV—Functional GI Disorders: Disorders of Gut-Brain InteractionGastroenterology, 2016
- Outcomes and Factors Associated With Reduced Symptoms in Patients With GastroparesisGastroenterology, 2015
- Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled StudyGastroenterology, 2015
- Surgical Approaches to Treatment of GastroparesisGastroenterology Clinics of North America, 2015
- Effect of Nortriptyline on Symptoms of Idiopathic GastroparesisJAMA, 2013
- Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record dataJournal of the American Medical Informatics Association, 2012
- Systematic review: cardiovascular safety profile of 5‐HT4agonists developed forgastrointestinaldisordersAlimentary Pharmacology & Therapeutics, 2012
- Risk of Gastroparesis in Subjects With Type 1 and 2 Diabetes in the General PopulationAmerican Journal of Gastroenterology, 2012
- A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adultsThe American Journal of Emergency Medicine, 2011
- The Incidence, Prevalence, and Outcomes of Patients With Gastroparesis in Olmsted County, Minnesota, From 1996 to 2006Gastroenterology, 2009